menu
    • menu
    [{"orgOrder":0,"company":"Sino Universal Pharmaceutical","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Tiotropium Bromide","moa":"Muscarinic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sino Universal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sino Universal Pharmaceutical \/ Sino Universal Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Sino Universal Pharmaceutical \/ Sino Universal Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sino Universal Pharmaceutical

    Menu

    Sino Universal Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sino Universal Pharmaceutical

                            Hong Kong arrow
                            APGA Annual Conference
                            Not Confirmed

                            Sino Universal Pharmaceutical

                            Hong Kong arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiotropium Bromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved FDF

                            Recipient : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lupin and Sino Universal Sign Deal for Tiotropium DPI Supply in China

                            Details : Under the licensing agreement, SUP will holds the right for the commercialization of Spiriva HandiHaler-Generic (Tiotropium Bromide) in the Chinese market for the treatment of COPD.

                            Product Name : Spiriva HandiHaler-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 16, 2025

                            Lead Product(s) : Tiotropium Bromide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth